The long serum of IgGs is ensured by their interaction with the neonatal Fc receptor (FcRn), which salvages IgG from intracellular degradation. Fc glycosylation is thought not to influence FcRn binding and IgG longevity in vivo. In this article, we demonstrate that hypersialylation of asparagine 297 (N297) enhances IgG serum persistence. This polarized glycosylation is achieved using a novel Fc mutation, a glutamate residue deletion at position 294 (Del) that endows IgGs with an up to 9-fold increase in serum lifespan. The strongest impact was observed when the Del was combined with Fc mutations improving FcRn binding (Del-FcRn). Enzymatic desialylation of a Del-FcRn mutant or its production in a cell line unable to hypersialylate reduced the in vivo serum of the desialylated mutants to that of native FcRn mutants. Consequently, our study proves that sialylation of the N297 sugar moiety has a direct impact on human IgG serum persistence.

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1800896DOI Listing

Publication Analysis

Top Keywords

fcrn binding
8
igg serum
8
serum persistence
8
serum
6
sialylation prolongs
4
prolongs serum
4
serum half-life
4
half-life therapeutic
4
therapeutic antibodies
4
antibodies long
4

Similar Publications

Downregulation of FcRn promotes ferroptosis in herpes simplex virus-1-induced lung injury.

Cell Mol Life Sci

January 2025

School of Basic Medical Sciences, Xinxiang Medical University, #601 Jinsui Road, Xinxiang, 453003, Henan, China.

Article Synopsis
  • HSV-1 infection can lead to lung injury, and a study found that lower levels of FcRn (a protein) are linked to more severe lung damage caused by the virus.
  • The study revealed that HSV-1 increases the methylation of the FcRn gene, which reduces its expression by promoting DNMT3b, a protein that inhibits transcription through a specific region of the FcRn promoter.
  • Inhibiting ferroptosis (a type of cell death) with a drug helped reduce lung injury in cases affected by HSV-1, indicating that targeting FcRn might be a promising therapeutic approach.
View Article and Find Full Text PDF

Introduction: Thymic stromal lymphopoietin (TSLP) is a master regulator of allergic inflammation against pathogens at barrier surfaces of the lung, skin, and gut. However, aberrant TSLP activity is implicated in various allergic, chronic inflammation and autoimmune diseases and cancers. Biologics drugs neutralizing excess TSLP activity represented by tezepelumab have been approved for severe asthma and are being evaluated for the treatments of other TSLP-mediated diseases.

View Article and Find Full Text PDF

Rozanolixizumab, a humanised immunoglobulin (Ig) G4 monoclonal antibody that selectively inhibits binding of IgG to the neonatal Fc receptor (FcRn), was evaluated in an embryo-foetal enhanced pre- and postnatal development (ePPND) study. Pregnant female cynomolgus monkeys (19 per group) received subcutaneous rozanolixizumab 50mg/kg or 150mg/kg or vehicle every 3 days from gestation day 20 until delivery. The proportion of pregnancy losses was 15.

View Article and Find Full Text PDF

Background: Cytokines have been promising cancer immunotherapeutics for decades, yet only two are licensed to date. Interleukin-12 (IL-12) is a potent regulator of cell-mediated immunity that activates NK cells and interferon-γ (IFNγ) production. It plays a central role in multiple pathways that can enhance cancer cell death and modify the tumor microenvironment (TME).

View Article and Find Full Text PDF

Background: Significant disparities in Group B Streptococcus (GBS) colonisation and neonatal disease rates have been documented across different geographical regions. For example, Bangladesh reports notably lower rates compared to the United Kingdom (UK) and Malawi. This study investigates whether this epidemiological variability correlates with the immune response to GBS in these regions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!